What it sells
Diversifying precision cancer diagnostics and treatments
Business model breakdown
Buyer: who owns the budget?
UnverifiedPatients and clinicians for diagnostics; pharma/research partners for data (inferred).
Workflow: what inputs become what output?
Clinical genomic research across Africa building a diverse cancer bio-database; in-house lab offers GeneStrat EGFR ctDNA blood test, Sheba HPV self-sampling test (results within five working days), SMA genetic testing.
Economics: what it saves and how it charges
UnverifiedDiagnostic and sequencing service fees plus research/data partnerships; venture-funded (OneBio second investment).
Distribution: how it reaches customers
Collection points for samples, partner network, cancer network research.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.